Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 68,178 |
|
|||||
| News | - | ||||||
| Day High | 2.00 | Low High |
|||||
| Day Low | 1.8201 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Exagen Inc | XGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.13 | 6.95% | 2.00 | 19:00:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.88 | 1.8201 | 2.00 | 2.00 | 1.87 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 629 | 68,178 | $ 1.91 | $ 130,557 | - | 1.3003 - 3.4712 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:54:57 | 47 | $ 2.0017 | USD |
Exagen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 34.09M | 17.05M | - | 52.55M | -23.69M | -1.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Exagen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.92 | 2.00 | 1.78 | 1.89 | 66,908 | 0.08 | 4.17% |
| 1 Month | 1.37 | 2.00 | 1.3188 | 1.73 | 63,058 | 0.63 | 45.99% |
| 3 Months | 1.92 | 2.29 | 1.3003 | 1.69 | 49,199 | 0.08 | 4.17% |
| 6 Months | 1.57 | 2.40 | 1.3003 | 1.81 | 53,636 | 0.43 | 27.39% |
| 1 Year | 3.16 | 3.4712 | 1.3003 | 1.92 | 33,811 | -1.16 | -36.71% |
| 3 Years | 13.27 | 17.58 | 1.3003 | 6.24 | 43,894 | -11.27 | -84.93% |
| 5 Years | 16.80 | 29.858 | 1.3003 | 10.60 | 46,594 | -14.80 | -88.10% |
Exagen Description
| Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
